Sustained Remission with Tocilizumab in Refractory Relapsing Polychondritis with Ocular Involvement: A Case Series.
Ocul Immunol Inflamm
; 29(1): 9-13, 2021 Jan 02.
Article
em En
| MEDLINE
| ID: mdl-32643976
ABSTRACT
Objective:
Describe our experience with tocilizumab in the treatment of refractory relapsing polychondritis with ocular involvement.Methods:
Retrospective consecutive interventional case series that included all patients that received tocilizumab for the treatment of relapsing polychondritis with ocular manifestations.Results:
Three cases were selected and the duration of tocilizumab treatment ranged from 1 to 2 years. One of our patients received tocilizumab as a first-line immunosuppressive treatment directly after prednisone. All achieved complete response to tocilizumab 1 month after treatment initiation. No advert events were reported during the follow-up period except for transient neutropenia without any associated infection.Conclusion:
Our three cases suggest that tocilizumab may be an effective and safe treatment for ocular manifestation associated with relapsing polychondritis.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Policondrite Recidivante
/
Indução de Remissão
/
Esclerite
/
Anticorpos Monoclonais Humanizados
Tipo de estudo:
Diagnostic_studies
/
Etiology_studies
/
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Limite:
Adult
/
Humans
/
Male
/
Middle aged
Idioma:
En
Ano de publicação:
2021
Tipo de documento:
Article